Sterling Drug
Executive Summary
Obtains an exclusive worldwide license from Xoma to the chimeric pan-carcinoma monoclonal antibody ING-1, which is currently in preclinical evaluation for a number of types of cancer. Xoma will receive a technology access fee and royalties from future product sales. Sterling, which will conduct all further development work on ING-1, will also receive a nonexclusive license to certain Xoma genetic engineering technologies for cancer applications. Xoma says the move is its first in connection with an earlier decision to license some of its cancer-related drug development programs and concentrate on products for infectious diseases and immune disorders. While Xoma's initial product development efforts have been with murine antibodies, the company's 1989 acquisition of Ingene provided chimeric monoclonal antibody technology.